News from Tuesday, March 4, 2025
Articles
R.I.P. VBID? (Part 2)
(3/4, Laura Beerman, HealthLeaders Media) reports “...In an environment where healthcare costs present considerable risk, can any option be taken off the table? Part II summarizes how the VBID model could succeed, the MA model lessons learned, and why value-based care in general must somehow achieve the impossible.” Full
After Canada Required Pharma to Pay Fees, Drug Agency Recommended Coverage More Often
(3/3, Ed Silverman, STAT+) reports “...After a Canadian agency began requiring application fees from drug companies more than a decade ago, the odds that a drug — other than cancer treatments — would receive a recommendation for government funding rose dramatically, according to a new study. And the author suggested the fees created a conflict of interest that may have influenced agency decision-making.” Subscription Required
Journals
Addressing Challenges with Matching-Adjusted Indirect Comparisons to Demonstrate the Comparative Effectiveness of Entrectinib in Metastatic ROS-1 Positive Non-Small Cell Lung Cancer
Cyril Esnault, et al.
March 1, 2025, BMC Medical Research Methodology
Data Linkage Multiplies Research Insights Across Diverse Healthcare Sectors
T. S. Karin Eisinger-Mathason, et al.
March 4, 2025, Communications Medicine
Misleading and Avoidable: Design-Induced Biases in Observational Studies Evaluating Cancer Screening -- The Example of Site-Specific Effectiveness of Screening Colonoscopy
Malte Braitmaier, et al.
March 4, 2025, medRxiv
Reports
Rotten to the Core: Inflation Reduction Act Undermines Medicare Part D, Pill Penalty Drug Costs Increase Up to 76%
February 28, 2025